ATE541573T1 - Pharmazeutische zusammensetzung enthaltend lapatinib - Google Patents

Pharmazeutische zusammensetzung enthaltend lapatinib

Info

Publication number
ATE541573T1
ATE541573T1 AT09782127T AT09782127T ATE541573T1 AT E541573 T1 ATE541573 T1 AT E541573T1 AT 09782127 T AT09782127 T AT 09782127T AT 09782127 T AT09782127 T AT 09782127T AT E541573 T1 ATE541573 T1 AT E541573T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
composition containing
lapatinib
containing lapatinib
composition
Prior art date
Application number
AT09782127T
Other languages
English (en)
Inventor
Katrin Rimkus
Frank Muskulus
Sandra Brueck
Jana Paetz
Original Assignee
Ratiopharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39884161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE541573(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ratiopharm Gmbh filed Critical Ratiopharm Gmbh
Application granted granted Critical
Publication of ATE541573T1 publication Critical patent/ATE541573T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT09782127T 2008-08-25 2009-08-24 Pharmazeutische zusammensetzung enthaltend lapatinib ATE541573T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08014984A EP2158913A1 (de) 2008-08-25 2008-08-25 Pharmazeutische Zusammensetzung mit N-[3-chlor-4-(3-fluorophenyl)methoxy)phenyl)6-(5(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furyl)-4-chinazolinamin
PCT/EP2009/060890 WO2010023188A1 (en) 2008-08-25 2009-08-24 Pharmaceutical composition comprising n-[3-chloro-4-[(3- fluorophenyl)methoxy]phenyl]-6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4- quinazolinamine

Publications (1)

Publication Number Publication Date
ATE541573T1 true ATE541573T1 (de) 2012-02-15

Family

ID=39884161

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09782127T ATE541573T1 (de) 2008-08-25 2009-08-24 Pharmazeutische zusammensetzung enthaltend lapatinib

Country Status (7)

Country Link
US (1) US8586091B2 (de)
EP (2) EP2158913A1 (de)
AT (1) ATE541573T1 (de)
CA (1) CA2735206C (de)
ES (1) ES2378134T3 (de)
RU (1) RU2011107140A (de)
WO (1) WO2010023188A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2958552B1 (de) 2013-02-19 2017-06-21 Hexal AG Pharmazeutische zusammensetzung mit n-[3-chlor-4-(3-fluorbenzyloxy)phenyl]-6-[5({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]chinazolin-4-amin oder ein pharmazeutisch akzeptables salz, solvat oder solvatisiertes salz daraus
TWI828027B (zh) 2016-03-28 2024-01-01 美商英塞特公司 作為tam抑制劑之吡咯并三嗪化合物
WO2018137020A1 (en) 2017-01-25 2018-08-02 Pacey Medtech Ltd. Distributed pressure fenestrated urethral compression apparatus for treatment of male urinary sphincter deficiency with preservation of blood flow
US10633387B2 (en) 2017-09-27 2020-04-28 Incyte Corporation Salts of TAM inhibitors
US11931368B2 (en) * 2017-09-29 2024-03-19 Crititech, Inc. Glucocorticoid “nintedanib” particles and their use
ES3031110T3 (en) 2018-06-29 2025-07-04 Incyte Corp Formulations of an axl/mer inhibitor
EP3846787A4 (de) * 2018-09-03 2022-05-25 BDR Pharmaceuticals International Private Limited Neuartige zusammensetzung von lapatinib in oraler fester darreichungsform und verfahren zu ihrer herstellung
PH12022552347A1 (en) 2020-03-06 2024-01-29 Incyte Corp Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
BR112023000501A2 (pt) 2020-07-23 2023-01-31 Crititech Inc Partículas de lapatinibe e usos das mesmas

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8623557D0 (en) * 1986-10-01 1986-11-05 Boots Co Plc Therapeutic agents
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
CA2413134C (en) 2000-06-30 2010-05-11 Glaxo Group Limited Quinazoline ditosylate salt compounds
US20040247689A1 (en) * 2003-03-26 2004-12-09 Guy Samburski Process for preparing a pharmaceutical active ingredient with high specific surface area
WO2005103017A1 (ja) 2004-04-20 2005-11-03 Ono Pharmaceutical Co., Ltd. 難溶性薬物の比表面積増大方法
BRPI0511754A (pt) 2004-06-03 2008-01-02 Smithkline Beechman Cork Ltd uso de um composto ou sais ou solvatos do mesmo
CA2571421A1 (en) 2004-06-24 2006-01-05 Nicholas Valiante Compounds for immunopotentiation
US20080306097A1 (en) 2004-12-17 2008-12-11 Smithkline Beecham (Cork) Limited Cancer Treatment Method
JP2008535924A (ja) 2005-04-12 2008-09-04 エラン ファーマ インターナショナル リミテッド ナノ粒子キナゾリン誘導体製剤
KR101356748B1 (ko) 2005-04-19 2014-02-06 스미스클라인 비이참 (코르크) 리미티드 약제 조성물
WO2007143483A2 (en) * 2006-06-01 2007-12-13 Smithkline Beecham Corporation Combination of pazopanib and lapatinib for treating cancer
US20100069411A1 (en) * 2006-11-28 2010-03-18 Smithkline Beecham (Cork) Ltd. Cancer treatment method
EP2158912A1 (de) * 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmazeutische Zusammensetzung mit N-[3-chlor-4-(3-fluorophenyl)methoxy)phenyl)6-(5(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furyl)-4-chinazolinamin
WO2010061400A1 (en) * 2008-11-03 2010-06-03 Natco Pharma Limited A novel process for the preparation of lapatinib and its pharmaceutically acceptable salts

Also Published As

Publication number Publication date
EP2158913A1 (de) 2010-03-03
EP2320902B1 (de) 2012-01-18
RU2011107140A (ru) 2012-09-27
CA2735206A1 (en) 2010-03-04
CA2735206C (en) 2016-11-01
ES2378134T3 (es) 2012-04-09
EP2320902A1 (de) 2011-05-18
US8586091B2 (en) 2013-11-19
US20110305762A1 (en) 2011-12-15
WO2010023188A1 (en) 2010-03-04

Similar Documents

Publication Publication Date Title
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
JO2973B1 (en) Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
CY1119474T1 (el) Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης
EA201500430A1 (ru) Соединения боронатного эфира и его фармацевтические составы
UA94942C2 (ru) Фармацевтические композиции с ингибиторами dpp iv
CY1109010T1 (el) γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ
BRPI0906064A2 (pt) "peptídeo, processo para obtenção de um peptídeo de fórmula geral (i), composição cosmética ou farmacêutica e uso de um peptídeo de fórmula geral (i)"
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
EA017764B8 (ru) Фармацевтическая композиция, способ ее получения и способ лечения вирусных заболеваний с ее использованием
EA200970500A1 (ru) СОЕДИНЕНИЯ ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА АНДРОГЕНОВ
EA200700168A1 (ru) Производные замещенной циклической мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназы
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
FR16C1025I1 (fr) Sel de 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
BR112014011981A2 (pt) formulações farmacêuticas
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
NO20071299L (no) Vedvarende frigivelse farmasoytisk sammensetning av tolterodine
EA200702253A1 (ru) Фармацевтическая композиция
MY150988A (en) Novel derivatives of ( bridged piperazinyl)-1-alkanone and use thereof as p75 inhibitors
GEP20146025B (en) Chromenone derivatives as trpv3 antagonists
WO2007076091A3 (en) Treatment of viral infections using a tissue factor inhibitor
EA200801614A1 (ru) Фармацевтическая композиция, содержащая монтелукаст
WO2007083096A3 (en) N- (2, 3-difluorophenyl) -2- [4- ( {7-methoxy-5- [ (2r) -piperidin. -2-ylmethoxy] quinazoli n-4-yl}amino) -lh-pyrazol-1-yl] acetamide and n- (2, 3 -d i fluoro phenyl) -2- [4- ( {7-ethoxy-5- [ (2r) -piperidin. -2-ylmethoxy] quinazolin
ATE496899T1 (de) Tetrahydro- und dihydrochinazolinone
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin